ACIU Stock Overview
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AC Immune SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.36 |
| 52 Week High | US$5.14 |
| 52 Week Low | US$2.25 |
| Beta | 1.28 |
| 11 Month Change | 12.00% |
| 3 Month Change | 4.02% |
| 1 Year Change | 4.67% |
| 33 Year Change | -31.15% |
| 5 Year Change | -56.59% |
| Change since IPO | -78.54% |
Recent News & Updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Shareholder Returns
| ACIU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 4.0% | 2.0% |
| 1Y | 4.7% | 18.0% | 32.4% |
Return vs Industry: ACIU underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: ACIU underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ACIU volatility | |
|---|---|
| ACIU Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACIU has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACIU's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 147 | Andrea Pfeifer | www.acimmune.com |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
AC Immune SA Fundamentals Summary
| ACIU fundamental statistics | |
|---|---|
| Market cap | US$336.40m |
| Earnings (TTM) | -US$45.19m |
| Revenue (TTM) | US$46.45m |
7.2x
P/S Ratio-7.4x
P/E RatioIs ACIU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACIU income statement (TTM) | |
|---|---|
| Revenue | CHF 40.97m |
| Cost of Revenue | CHF 61.43m |
| Gross Profit | -CHF 20.46m |
| Other Expenses | CHF 19.41m |
| Earnings | -CHF 39.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -49.93% |
| Net Profit Margin | -97.29% |
| Debt/Equity Ratio | 0% |
How did ACIU perform over the long term?
See historical performance and comparison